KRP-209 (Neramexane) By Kyorin

"KRP-209 (Neramexane) is expected to improve the patients' annoyance and difficulties in their life caused by tinnitus, mainly through its two pharmacological properties: 1) NMDA antagonistic activity and 2) Nicotinic acetylcholine antagonistic activity."

http://www.kyorin-gr.co.jp/en/ir/rd/pipeline.shtml

I read it in Kanji and finally found an English version.

At least we may have some other hopes from this Japanese Medicine Company? Neramexane seems like a failed product though?

 

Any further news about this?

 

It's failed.

 

It is strange, it seems apparently still current according to this link:
http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-152984

 

According to a Tinnitus market analysis (recent) Merz is still listed as a 'player' in the tinnitus market.

@Aaron123 Are you aware or up to date with this company/compound?

 

Source?

 

"Companies Involved in Tinnitus Therapeutics Development:
AudioCure Pharma GmbH, Auris Medical Holding AG, Knopp Biosciences LLC, Merz Pharma GmbH & Co KgaA, Otonomy Inc., Pragma Therapeutics SAS, SciFluor Life Sciences LLC, Sound Pharmaceuticals Inc."

https://www.medgadget.com/2017/09/g...gs-clinical-reviews-and-company-analysis.html

 

I wonder if anybody has access to the full article?

 

You wouldn't need to buy the report just to see information about Merz, a simple email to them asking for all the information they can tell you about their tinnitus pipeline would do it.

 

According to their website, KRP-209 is still in phase 2 (and has been since August 2015).

 

I'm not. There was a Phase II trial (https://clinicaltrials.gov/ct2/show/NCT00405886) with published results (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031239/pdf/1472-6815-11-1.pdf).

The resulting Phase 3 trial was terminated: https://clinicaltrials.gov/ct2/show/NCT00827008.

There was a Phase 1 trial in Japanese subjects (though the location given is in the US): https://clinicaltrials.gov/ct2/show/NCT00983099 that had Merz involvement.

And the Phase 2 trial that may or may not be on-going. The last information on Kyorin's web site is from 2015. The March 31, 2017 annual report (http://www.kyorin-gr.co.jp/en/ir/pdf/ar17/AR2017EN.pdf) still lists it as a Phase II product as of 8/2015 but also says "redeveloping" so I am not sure what to make of that. It seems unlikely that anything will come of this.